GLP1R has recently been implicated as a multimodal receptor involved in cardiometabolic disease and is targeted by several US Food and Drug Administration–approved drugs for the treatment of type 2 diabetes and obesity (30–32). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.